Given that IDH mutations may adversely affect outcome in MDS are relatively easy to assess at diagnosis, examining IDH mutations in MDS may enhance the current prognostic scoring systems and guide patient-specific treatment in MDS. Here, IDH2 is linked to myelodysplastic syndrome.